FDA Employees Were ‘Granting Approval Without Knowing Why,’ Judge Rules In Ranbaxy Case
This article was originally published in The Pink Sheet Daily
Executive Summary
But court finds FDA has authority to correct its mistakes and revoke Ranbaxy’s tentative ANDA approvals
You may also be interested in...
Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.
With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth
Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than the industry average in most key markets, and at the same time look to remediate the troubled manufacturing sites of Ranbaxy. Management also indicated that it might not appeal against the recent U.S. Court ruling on generic Nexium.
Ranbaxy Exclusivity Implosion Pushes Valcyte Generics Towards Launch; Nexium Remains ‘Very Hazy’
FDA rescinds Ranbaxy’s esomeprazole and valganciclovir ANDA tentative approvals because of GMP compliance issues; firm loses its 180-day marketing exclusivity for valganciclovir but not for esomeprazole.